Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies.
Tomoki SakakidaTakeshi IshikawaY ChiharaS HaritaJ UchinoY TabuchiS KomoriJ AsaiT NarukawaA AraiH TsunezukaT KosugaH KonishiM MoriguchiH YasudaF HongoM InoueS HiranoO UkimuraY ItohT TaguchiK TakayamaPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2019)
Further studies to identify predictive factors for the development of irAEs are required to provide relevant patient care and maximize the therapeutic benefits of ICIs.
Keyphrases